Grant: Engage Plus Grants Program
University of Guelph
$12,406.00
Phytoglycogen nanoparticles as a technology platform for engineered anti-infective agents
EF 2016-17
Résumé
PhytoSpherixTM nanoparticles are a nontoxic, biodegradable proprietary biomaterial generated by Mirexus Inc. (Guelph, ON) from Ontario-grown sweet corn. Each nanoparticle consists of a single molecule of highly-branched glucose homopolymer, providing a uniform surface physico-chemistry to which active ingredients can be conjugated. PhytoSpherixTM is especially suited for use in a wide range of applications for nutraceuticals, cosmetics, pharmaceuticals and biomedical applications. It can be modified by adding functional groups or various active pharmaceutical ingredients e.g. antibiotics. This last feature is pertinent: over the last decades few new antibiotics have entered the market, which is a globally-recognised concern. Strong interest in novel antimicrobials has driven research in nano-enabled delivery systems. While the concept of targeted drug delivery has been proven, the search continues for novel nanoparticulate carriers which are non-toxic and safe, monodisperse, water soluble and easy to modify. PhytoSpherixTM has these desirable properties and is therefore an attractive lead for exploitation.The NSERC Engage grant awarded to Mirexus Inc. and Dr. Glasauer (University of Guelph) has led to the development of a functional antifungal-PhytoSpherixTM conjugate. Research to generate antibacterial conjugates is ongoing. This EngagePlus application will support us in completing the development of Phytospherix-based antibacterial compounds and testing their efficacy against pathogenic bacteria. We are particularly interested in the ability of the antibacterial conjugates to disrupt the attachment of bacteria to surfaces and initiation of biofilm formation, key factors in bacterial virulence.
Programme
Engage Plus Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
494633-2016
Name nom
Glasauer, Susan
Department département
Environmental Sciences, School of
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
12406
Program id
EGP2
Program name en
Engage Plus Grants Program
Program name fr
Programme de subvention d'engagement partenarial Plus
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
6404
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Pharmacology
Research subject fr
Pharmacologie
Partie
1
Nb partie
1
Application title
Phytoglycogen nanoparticles as a technology platform for engineered anti-infective agents
Keyword
NSERC
Application summary
PhytoSpherixTM nanoparticles are a nontoxic, biodegradable proprietary biomaterial generated by Mirexus Inc. (Guelph, ON) from Ontario-grown sweet corn. Each nanoparticle consists of a single molecule of highly-branched glucose homopolymer, providing a uniform surface physico-chemistry to which active ingredients can be conjugated. PhytoSpherixTM is especially suited for use in a wide range of applications for nutraceuticals, cosmetics, pharmaceuticals and biomedical applications. It can be modified by adding functional groups or various active pharmaceutical ingredients e.g. antibiotics. This last feature is pertinent: over the last decades few new antibiotics have entered the market, which is a globally-recognised concern. Strong interest in novel antimicrobials has driven research in nano-enabled delivery systems. While the concept of targeted drug delivery has been proven, the search continues for novel nanoparticulate carriers which are non-toxic and safe, monodisperse, water soluble and easy to modify. PhytoSpherixTM has these desirable properties and is therefore an attractive lead for exploitation.The NSERC Engage grant awarded to Mirexus Inc. and Dr. Glasauer (University of Guelph) has led to the development of a functional antifungal-PhytoSpherixTM conjugate. Research to generate antibacterial conjugates is ongoing. This EngagePlus application will support us in completing the development of Phytospherix-based antibacterial compounds and testing their efficacy against pathogenic bacteria. We are particularly interested in the ability of the antibacterial conjugates to disrupt the attachment of bacteria to surfaces and initiation of biofilm formation, key factors in bacterial virulence.